Journal of
eISSN: 2374-6947
Submit manuscript...
Review Article Volume 13 Issue 1
Breaking the complexity of T2D management with iGlarLixi: a simplified innovation in T2DM management paradigm
Shambo Samrat Samajdar, Rupak Chatterjee, Shatavisa Mukherjee, Shashank Joshi
Received: January 28, 2026 | Published: February 16, 2026
Citation: Samajdar SS, Chatterjee R, Mukherjee S, et al. Breaking the complexity of T2D management with iGlarLixi: a simplified innovation in T2DM management paradigm. J Diabetes Metab Disord Control. 2026;13(1):8-12. DOI: 10.15406/jdmdc.2026.13.00305
Abstract
Type 2 Diabetes Mellitus (T2DM) is a multifaceted metabolic disorder characterized by chronic hyperglycemia resulting from insulin resistance, impaired insulin secretion, or both. Effective management of T2DM necessitates a comprehensive approach, integrating lifestyle modifications, oral antidiabetic drugs (OADs), and injectable therapies. iGlarLixi, a fixed-ratio combination of insulin glargine (a long-acting insulin) and lixisenatide (a GLP-1 receptor agonist), emerges as a novel therapeutic strategy aimed at simplifying T2DM management. This article examines the efficacy, safety, and clinical implications of iGlarLixi, drawing on insights from clinical studies and prescribing information.
Keywords: iGlarLixi, insulin glargine, lixisenatide, efficacy, safety, clinical implications
©2026 Samajdar, et al. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.